2 citations
,
May 2025 in “Journal of Clinical Medicine” This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.
20 citations
,
July 2024 in “Archives of Dermatological Research” This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.
6 citations
,
May 2023 in “Drugs” This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
20 citations
,
February 2023 in “American Journal of Clinical Dermatology” In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.
9 citations
,
January 2023 in “Dermatology and therapy” This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.
7 citations
,
January 2022 in “SAGE open medical case reports” This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.
